A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron Versus PEGASYS in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 03 Feb 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 07 Jan 2016 Planned End Date changed from 1 Feb 2016 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 07 Jan 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jan 2016, according to ClinicalTrials.gov record.